Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

AstraZeneca wins FDA approval for Calquence in chronic lymphoma

Takes the fight to AbbVie and J&J's lymphoma rival Imbruvica

- PMLiVE

J&J’s new Darzalex formulation OK’d for use in Europe

Extends use of multiple myeloma therapy even further

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

- PMLiVE

J&J catches up to Merck, files Ebola vaccine in Europe

Company is also in discussion with the FDA in the US to support regulatory filings

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

- PMLiVE

UPDATED: Ohio opioid trial averted by last-minute settlement

Drug manufacturers reach settlement hours before trial set to begin

- PMLiVE

Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis

- PMLiVE

Johnson & Johnson agrees $20.4m settlement in Ohio over opioid crisis

Will avoid upcoming federal trial as a result

- PMLiVE

J&J expands Darzalex use with another first-line FDA approval

Could help defend myeloma franchise against rival Sanofi

- PMLiVE

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication

- PMLiVE

J&J’s Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

- PMLiVE

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Regulatory filings expected in first half of 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links